Radioactive injection targets Hard-to-Treat breast cancer in early trial
NCT ID NCT07340424
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a radioactive drug called 225Ac-TR2205 in 15 women with advanced triple-negative breast cancer that has spread. The main goal is to see if the drug is safe and tolerable, and to measure how much radiation reaches tumors. It is too early to know if it works, but researchers hope it may one day offer a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
225Ac-TR2205 injection (a radioactive drug)
What this could lead to
If it works, this could point toward a new treatment option for advanced triple-negative breast cancer that has spread.
What could go wrong
This is a very early, small trial (15 people) focused on safety, not effectiveness. The radioactive drug may cause side effects, and it's unknown if it will shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China